Quick Takeaways
- This page summarizes Pablo J. Cagnoni's Form 4 filing for INCYTE CORP (INCY).
- 5 reported transactions and 2 derivative rows are listed below.
- Filing timestamp: 19 Mar 2026, 16:20.
Pablo J. Cagnoni - 17 Mar 2026 Form 4 Insider Report for INCYTE CORP (INCY)
- Role
- President, R&D
- Signature
- /s/ Elizabeth Feeney, Attorney-In-Fact
- Issuer symbol
- INCY
- Transactions as of
- 17 Mar 2026
- Net transactions value
- -$1,759,178
- Form type
- 4
- Filing time
- 19 Mar 2026, 16:20:22 UTC
- Previous filing
- 23 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Pablo J. Cagnoni filed Form 4 for INCYTE CORP (INCY) on 19 Mar 2026."
What Changed
- Previous filing in this sequence was filed on 23 Feb 2026.
- Current net transaction value: -$1,759,178.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Reporting Owners (1)
| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| CAGNONI PABLO J | President, R&D | 1801 AUGUSTINE CUT-OFF, WILMINGTON | /s/ Elizabeth Feeney, Attorney-In-Fact | 19 Mar 2026 | 0001205703 |
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INCY | Common Stock | Options Exercise | +7,166 | +3.1% | $61.18* | 241,966 | 17 Mar 2026 | Direct | ||
| transaction | INCY | Common Stock | Options Exercise | +11,501 | +4.8% | $64.25* | 253,467 | 17 Mar 2026 | Direct | ||
| transaction | INCY | Common Stock | Sale | $1,759,178 | -18,667 | -7.4% | $94.24 | 234,800 | 17 Mar 2026 | Direct | F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INCY | Employee Stock Option (right to buy) | Options Exercise | -7,166 | -44% | $0.000000* | 9,102 | 17 Mar 2026 | Common Stock | 7,166 | $61.18 | Direct | F2 | |
| transaction | INCY | Employee Stock Option (right to buy) | Options Exercise | -11,501 | -26% | $0.000000* | 32,910 | 17 Mar 2026 | Common Stock | 11,501 | $64.25 | Direct | F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | This includes an aggregate of 229,661 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. |
| F2 | Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years. |
| F3 | The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. |